$ALPN News
Last published 1y ago
- 1y agoALPNFrazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture PartnersBusiness WireFrazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture
- 2y agoALPNORICAttovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of DirectorsGlobeNewswireFREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You
- 2y agoALPNVRTXAlpine Immune Sciences Reports First Quarter 2024 Financial ResultsBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the
- 2y agoALPNJBTELYMHRTKuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoALPNAlpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA NephropathyBusiness Wire-- Povetacicept administered subcutaneously once every four weeks continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 weeks, associated with remission, resolution
- 2y agoALPNVRTXVertex Enters Into Agreement to Acquire Alpine Immune SciencesBusiness Wire- Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine's lead product, povetacicept, demonstrated best-in-class potential in
- 2y agoALPNAlpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024Business Wire-- The Company will present updated data in a late-breaking poster session for povetacicept in IgA nephropathy patients -- -- The Company will host an investor event the same day concurrently with the poster
- 2y agoALPNAlpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024Business Wire-- Povetacicept demonstrates greater reductions in disease activity in a mouse model of lupus compared to WT TACI-Ig or B cell depletion -- -- Povetacicept exhibits greater distribution to disease-related end organs
- 2y agoALPNAlpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will
- 2y agoALPNAlpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoALPNAlpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial ResultsBusiness Wire-- Clinical data on povetacicept in IgA nephropathy will be updated at the upcoming WCN meeting, including follow up at 80 mg and initial data at 240 mg SC once every four-weeks -- -- Povetacicept advancing towards a
- 2y agoALPNAlpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial ResultsBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release
- 2y agoALPNAlpine Immune Sciences to Participate in Two Upcoming Healthcare ConferencesBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will
- 2y agoALPNAlpine Immune Sciences to Participate in Two Upcoming Healthcare ConferencesBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will
- 2y agoALPNAlpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVieBusiness Wire-- Enrollment in the phase 2 study of acazicolcept in systemic lupus erythematosus (Synergy) will be stopped to allow for early assessment of data -- -- Final analysis after last patient completes study protocol
- 2y agoALPNAlpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that Mitchell Gold, M.D.,
- 2y agoALPNAlpine Immune Sciences to Participate in the Evercore ISI HealthconX ConferenceBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will
- 2y agoALPNAlpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023Business Wire--Povetacicept Superior to Wild-Type TACI-Fc and B-cell Depletion in a Preclinical Model of Lupus-- -- Initiation of Phase 2 SLE Study Planned for 2H 2024 -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading
- 2y agoALPNAlpine Immune Sciences Reports Third Quarter 2023 Financial ResultsBusiness Wire-- First clinical data with povetacicept presented at American Society of Nephrology Kidney Week support best-in-class potential and broad pipeline opportunity – -- Company closed an oversubscribed $150 million equity
- 2y agoALPNAlpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023Business Wire-- Phase 2 Study in SLE (Synergy) Ongoing -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory
- 3y agoALPNAlpine Immune Sciences Announces Pricing of $150 Million Public OfferingBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the pricing of its underwritten
- 3y agoALPNAlpine Immune Sciences Announces Proposed Public OfferingBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that it has commenced an
- 3y agoALPNAlpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual MeetingBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company presented new
- 3y agoALPNAlpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023Business Wire-- Low-dose povetacicept (80 mg administered once every four weeks) was well tolerated during subcutaneous administration and reduced UPCR by greater than 50% in IgA nephropathy -- -- Higher dose povetacicept (240 mg)
- 3y agoALPNAlpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023Business WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present new
- 3y agoALPNAlpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023Business Wire-- The Company will host an investor event following the presentation after the close of market on Thursday, November 2nd -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company
- 3y agoALPNAlpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)Business WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of
- 3y agoALPNAlpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual MeetingBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company presented new
- 3y agoALPNAlpine Immune Sciences to Participate in Two Upcoming Healthcare ConferencesBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will
- 3y agoALPNAlpine Immune Sciences to Present First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual MeetingBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company will present
- 3y agoALPNAlpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)Business WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the successful initiation of the
- 3y agoALPNAlpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)Business WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of M.
- 3y agoALPNAlpine Immune Sciences Reports Second Quarter 2023 Financial ResultsBusiness Wire--The Company will present preliminary data from RUBY-3 glomerulonephritis clinical study at the American Society of Nephrology Meeting in November 2023-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading
- 3y agoALPNAlpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific CongressesBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present data
- 3y agoALPNAlpine Immune Sciences Reports First Quarter 2023 Financial ResultsBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the
- 3y agoALPNAlpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare ConferenceBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will
- 3y agoALPNAlpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsBusiness WireRUBY-3, a basket study of povetacicept in autoimmune glomerulonephritis, has initiated patient enrollment; RUBY-4, a basket study of povetacicept in autoimmune cytopenias, targets initiation in Q2 2023 Initial data
- 3y agoALPNTruveta and Alpine Immune Sciences Announce Strategic Partnership to Access Truveta's Community to Accelerate Recruitment to Povetacicept Clinical TrialsGlobeNewswireBELLEVUE and SEATTLE, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Today, Truveta and Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced a strategic partnership to help accelerate clinical trial recruitment for
- 3y agoALPNAlpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific ConferencesBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American
- 3y agoALPNAlpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual MeetingBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present an ePoster with an oral
- 3y agoALPNAlpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial ResultsBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release
- 3y agoALPNAn Open-label Study of ALPN-303 in Subjects With Autoimmune Cytopenias - NCT05757570ClinicalTrials.govAdverse Events
- 3y agoALPNAlpine Immune Sciences to Participate in Two Upcoming Healthcare ConferencesBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will participate in two upcoming
- 3y agoALPNAlpine Immune Sciences to Participate in the SVB Securities Global Biopharma ConferenceBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will present a
- 3y agoALPNAlpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx ConferenceBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will
- 4y agoALPNAlpine Immune Sciences to Report Third Quarter 2022 Financial ResultsBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release
- 4y agoALPNAlpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & ExpositionBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have a poster presentation for
- 4y agoALPNAlpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific ConferencesBusiness WireAlpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have poster presentations for
- 4y agoALPNAlpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)Business Wire- Company's primary focus will be the pursuit of expedited development plans for ALPN-303 in multiple autoimmune and inflammatory indications - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage
- 4y agoALPNANABFLACPHATPhathom Pharmaceuticals Appoints Dr. James Topper to its Board of DirectorsGlobeNewswireFLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the